Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Effect of a Dietary Supplement Versus Placebo on Serum PFAS Levels in Male Firefighters

Cambiotics ApS · with Atlantia Food Clinical Trials · NCT07846371

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · Men only
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
70
US sites recruiting
1
Study start
October 8, 2026
Record last updated
October 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study is designed to evaluate the effect of a probiotic dietary supplement containing Streptococcus salivarius on serum PFAS levels in male firefighters with documented occupational PFAS exposure, following twice-daily use over a 12-week period.

Being studied: Streptococcus salivarius 46-SL1; Placebo

Conditions: Environmental Exposure; PFAS Exposure

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Able to give written informed consent
  • Male firefighter with previous career exposure to PFAS
  • BMI between 18.5 and 35 kg/m²
  • Serum PFOS level ≥5 ng/mL at screening
  • Willing to consume the study product daily for the duration of the study

Exclusion Criteria

  • History of drug and/or alcohol abuse (>15 standard drinks per week)
  • Food allergy, intolerance or dietary restriction that, in the opinion of the investigator, would preclude consumption of the study product
  • Blood donation within the past 3 months
  • Current smoker of >20 cigarettes per day, or former smoker with a history of ≥20 cigarettes per day who quit within 6 months prior to Visit 1
  • Any significant acute or chronic health condition that would prevent participation, pose a risk, or confound interpretation of results, including: diagnosed gastrointestinal disorders (irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, coeliac disease, or other chronic diarrhoeal disorders); uncontrolled medical conditions; history of chronic kidney or liver disease; chronic inflammatory or autoimmune disease; history of gastrointestinal surgery; hospitalisation within the past 3 months
  • Current or recent (past 12 weeks) use of medications affecting bile acid metabolism (e.g. bile acid sequestrants, fibrates) or antibiotics
  • Current or recent (past 4 weeks) use of supplements affecting gut microbiota (prebiotics, probiotics, postbiotics, fibres, synbiotics), detoxification pathways (milk thistle, N-acetylcysteine, glutathione) or bile acid metabolism (e.g. psyllium husk)
  • Current or recent (past 2 weeks) consumption of prohibited foods, including probiotic yoghurts
  • Considered by the investigator unlikely to comply with study requirements
  • Current participation in another clinical study, or insufficient time elapsed since a previous experimental study

Recruiting US locations

  • Atlantia Clinical Trials

    Chicago, IL 60611

    Site contact: Abigail O'Mahony · +1 312 535-9440 · aomahoney@atlantiatrials.com

Study contacts (from the official record)

  • Abigail O'Mahony, Operations Manager · +1 312 535-9440 · aomahoney@atlantiatrials.com
  • Stacey Boetto, Princpal Investigator, DNP, FNP-C · 312-535-9440 · sboetto@atlantiatrials.com
Effect of a Dietary Supplement Versus Placebo on Serum PFAS Levels… (NCT07846371) | Bored Studies